US 12,728,119 B2
Pharmaceutical composition for preventing or treating cancer comprising 3-ketoacyl CoA thiolase inhibitor and carnitine acylcarnitine carrier inhibitor
Sooyoul Kim, Goyang-si (KR)
Assigned to NEW CANCER CURE-BIO CO., LTD., Goyang-si (KR)
Appl. No. 18/004,009
Filed by NATIONAL CANCER CENTER, Goyang-si (KR)
PCT Filed Jul. 1, 2021, PCT No. PCT/KR2021/008362
§ 371(c)(1), (2) Date Dec. 30, 2022,
PCT Pub. No. WO2022/005228, PCT Pub. Date Jan. 6, 2022.
Claims priority of application No. 10-2020-0080973 (KR), filed on Jul. 1, 2020.
Prior Publication US 2023/0255947 A1, Aug. 17, 2023
Int. Cl. A61K 31/495 (2006.01); A61K 31/194 (2006.01); A61K 31/4439 (2006.01); A61K 38/02 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61P 35/00 (2006.01); A61P 43/00 (2006.01); C07F 5/02 (2006.01)
CPC A61K 31/4439 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 9 Claims
OG exemplary drawing
 
1. A pharmaceutical composition for treating pancreatic cancer, comprising a 3-ketoacyl CoA thiolase (ACAA) inhibitor and a carnitine acylcarnitine carrier (CAC) inhibitor,
wherein the ACAA inhibitor is trimetazidine, ranolazine, or a pharmaceutically acceptable salt thereof, and
wherein the CAC inhibitor is omeprazole, lansoprazole, pantoprazole, or a pharmaceutically acceptable salt thereof.